Safety profile of upadacitinib in rheumatoid arthritis: integrated analysis from the SELECT phase III clinical programme

Cohen Stanley B.; van Vollenhoven Ronald F.; Winthrop Kevin L.; Zerbini Cristiano A. F.; Tanaka Yoshiya; Bessette Louis; Zhang Ying; Khan Nasser; Hendrickson Barbara; Enejosa Jeffrey V; Burmester Gerd R.

首页> 外文期刊>Annals of the Rheumatic Diseases: A Journal of Clinical Rheumatology and Connective Tissue Research >Safety profile of upadacitinib in rheumatoid arthritis: integrated analysis from the SELECT phase III clinical programme

【24h】

Safety profile of upadacitinib in rheumatoid arthritis: integrated analysis from the SELECT phase III clinical programme

机译：类风湿性关节炎uPadacitinib的安全性曲线：Select III阶段临床计划的综合分析

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Objectives This integrated analysis presents the safety profile of upadacitinib, a Janus kinase inhibitor, at 15 mg and 30 mg once daily in patients with moderately to severely active rheumatoid arthritis (RA).

机译：None

著录项

来源
《Annals of the Rheumatic Diseases: A Journal of Clinical Rheumatology and Connective Tissue Research》 |2021年第3期|共8页
作者
Cohen Stanley B.; van Vollenhoven Ronald F.; Winthrop Kevin L.; Zerbini Cristiano A. F.; Tanaka Yoshiya; Bessette Louis; Zhang Ying; Khan Nasser; Hendrickson Barbara; Enejosa Jeffrey V; Burmester Gerd R.;
展开▼
作者单位

Metroplex Clin Res Ctr Dallas TX 75231 USA;

Amsterdam Rheumatol &

Immunol Ctr Amsterdam Netherlands;

Oregon Hlth &

Sci Univ Portland OR 97201 USA;

Ctr Univ Cent Paulista Sao Paulo Brazil;

Univ Occupat &

Environm Hlth Japan Kitakyushu Fukuoka Japan;

Laval Univ Quebec City PQ Canada;

AbbVie Inc N Chicago IL USA;

AbbVie Inc N Chicago IL USA;

AbbVie Inc N Chicago IL USA;

AbbVie Inc N Chicago IL USA;

Charite Univ Med Berlin Berlin Germany;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类免疫性疾病;
关键词

相似文献

外文文献
中文文献
专利

1. Leflunomide, a new disease-modifying drug for treating active rheumatoid arthritis in methotrexate-controlled phase Ⅱ clinical trial [J] . 鲍春德, 陈顺乐, 顾越英, 中华医学杂志（英文版） . 2003,第008期
2. Analysis of Closed Claims in the Clinical Management of Rheumatoid Arthritis in Japan [J] . Yasuhiro Otaki, Makiko DaSilva Ishida, Yuichi Saito, 中华医学杂志（英文版） . 2017,第012期
3. Correction: Safety profile of upadacitinib in rheumatoid arthritis: integrated analysis from the SELECT phase III clinical programme [J] . Annals of the Rheumatic Diseases: A Journal of Clinical Rheumatology and Connective Tissue Research . 2021,第5期

机译：校正：upadacitinib在类风湿性关节炎中的安全性曲线：选择III期临床计划的综合分析
4. Efficacy and safety of upadacitinib in Japanese patients with rheumatoid arthritis (SELECT-SUNRISE): a placebo-controlled phase IIb/III study [J] . Kameda Hideto, Takeuchi Tsutomu, Yamaoka Kunihiro, Rheumatology . 2020,第11期

机译：日本类风湿性关节炎患者Upadacitinib的疗效和安全性（选择 - 日出）：安慰剂对照阶段IIB / III研究
5. Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT): a randomised, double-blind, placebo-controlled phase 3 trial [J] . Burmester Gerd R., Kremer Joel M., Van den Bosch Filip, The Lancet . 2018,第10139期

机译：upadacitinib在类风湿性关节炎患者中的安全性和疗效和对常规合成疾病改性抗风湿药物的反应不足（选择 - 下一步）：随机，双盲，安慰剂控制第3期试验
6. Immunogenic HLA-DR-presented-peptides Identified from Clinical Samples of Synovial Tissue/Fluid and Peripheral Blood from Patients with Rheumatoid Arthritis or Lyme Arthritis [C] . Qi Wang, Elise E. Drouin, Chunxiang Yao, ASMS Conference on Mass Spectrometry and Allied Topics . 2016

机译：免疫原性HLA-DR呈递肽，从类风湿性关节炎或莱姆关节炎患者的滑膜组织/液体和外周血的临床样本中鉴定出来
7. Clinical research on the preventive efficacy of sulfasalazine against Pneumocystis jirovecii pneumonia in patients with rheumatoid arthritis [D] . 布川貴博 2019

机译：柳氮磺胺吡啶对类风湿关节炎肺炎克氏杆菌的预防作用的临床研究
8. Exposure–Response Analyses of Upadacitinib Efficacy and Safety in Phase II and III Studies to Support Benefit–Risk Assessment in Rheumatoid Arthritis [O] . Ahmed Nader, Mohamed‐Eslam F. Mohamed, Insa Winzenborg, -1

机译：Upadacitinib有效性和安全性的II期和III期暴露-反应分析以支持类风湿关节炎的获益-风险评估
9. SAFETY PROFILE OF UPADACITINIB IN RHEUMATOID ARTHRITIS: INTEGRATED ANALYSIS FROM THE SELECT PHASE 3 CLINICAL PROGRAM. [O] . CRISTIANO AUGUSTO DE FREITAS ZERBINI 2019

机译：uPAdacitinib在类风湿性关节炎中的安全谱：精选第3期临床节目的综合分析。
10. Guidance for Industry. Clinical Development Programs for Drugs, Devices, and211 Biological Products for the Treatment of Rheumatoid Arthritis (RA) [R] . 1999

机译：工业指南。用于治疗类风湿性关节炎（Ra）的药物，设备和211生物制品的临床开发计划

Safety profile of upadacitinib in rheumatoid arthritis: integrated analysis from the SELECT phase III clinical programme

摘要

著录项

相似文献

相关主题

期刊订阅